Discovery & Development Europe 2025: Formulation & Drug Delivery Congress
July 1-2, 2025
Basel, Switzerland

Invited lecture:
Oral Delivery Of Peptide And Protein Drugs – Oral Delivery of GLP-1 Analogues

Prof. Dr. A. Bernkop-Schnürch
more...

8th European Cyclodextrin Conference
September 9-12, 2025
Milano, Italy

Invited lecture:
Thiolated Cyclodextrins in Drug Delivery

Prof. Dr. A. Bernkop-Schnürch
more...

Contract services: Non-IP based, fee for service, formulation development

If you want to keep all in your hands but ensure to have experienced experts doing the drug delivery work for you, contract service is the type of choice. ThioMatrix can assist you in your formulation development activities. Please contact us to discuss the services we can offer you.

Feasibility agreements

ThioMatrix performs proof-of-concept studies. We are convinced that our technologies are advantageous for many drugs. In order to see the great potential of our technologies for your drug please contact us.

Co-development

ThioMatrix is actively seeking partners to enter into new product development collaborations. If you have a potent drug but no appropriate delivery system for it, a co-development will offer you the following advantages:

• the combination of your drug with an efficient delivery system will lead to a marketable product in a comparatively shorter time
  
  
• additional intellectual property can be generated strengthening the patent portfolio of both partners and prolonging lifecycle of the resulting product
  
  
• developing an alternative, more convenient drug delivery system (e.g. oral versus subcutaneous injection) will put the co-developed product ahead of competitors
  
  

Starting a project

From single experiment analytical studies up to fully out-sourced developmental programs all projects can be initiated within a month by undertaking the following steps:

• Contact with our CSO Prof. Dr. Andreas Bernkop-Schnürch
  on +43 650 753 6270 or a.bernkop[AT]thiomatrix.com to initiate discussions
  
  
• Signing a confidentiality disclosure agreement to facilitate further discussions
  
  
• Transfer of Check-List for new projects in which all information we need from your side for the project is listed
  
  
• Based on data having been transferred to us and on face-to-face meetings or teleconferences a cost-free project proposal outlining the studies to be conducted and goals to be achieved, as well as associated time lines and costs is sent to youdeveloping an alternative, more convenient drug delivery system (e.g. oral versus subcutaneous injection) will put the co-developed product ahead of competitors
  
  
• Within a week after acceptance, a detailed Study Protocol according to GLP guidelines is sent to you
  
  
• Upon Study Protocol acceptance, we will carry out the studies as agreed
  
  
• During the project Interim Reports and upon project completion a Final Report will be sent to you. Furthermore, during the project and upon completion presentations will be given to discuss the project progress and results
  
  

License in/out

ThioMatrix is licensing out the thiomer-technology for companies, whose drug(s) is (are) protected by patents at least for the next 5-10 years. ThioMatrix is licensing in peptide drugs, efflux pump substrate drugs and class III drugs according to the BCS which can so far not be administered via non-invasive routes.

Thiomatrix joined the EU-project TENTACLE (101191747) focusing on the use of thiomers for in situ bioprinting.
more....